Your browser doesn't support javascript.
loading
Pathway level alterations rather than mutations in single genes predict response to HER2-targeted therapies in the neo-ALTTO trial.
Shi, W; Jiang, T; Nuciforo, P; Hatzis, C; Holmes, E; Harbeck, N; Sotiriou, C; Peña, L; Loi, S; Rosa, D D; Chia, S; Wardley, A; Ueno, T; Rossari, J; Eidtmann, H; Armour, A; Piccart-Gebhart, M; Rimm, D L; Baselga, J; Pusztai, L.
Afiliación
  • Shi W; Department of Breast Medical Oncology, Yale University, Yale Cancer Center, New Haven, USA.
  • Jiang T; Department of Breast Medical Oncology, Yale University, Yale Cancer Center, New Haven, USA.
  • Nuciforo P; Vall d'Hebron Institute of Oncology, Barcelona, Spain.
  • Hatzis C; Department of Breast Medical Oncology, Yale University, Yale Cancer Center, New Haven, USA.
  • Holmes E; Frontier Science, Inverness, Scotland.
  • Harbeck N; Breast Center, Department of Obstetrics and Gynecology, University of Munich, Germany.
  • Sotiriou C; Institut Jules Bordet, Université Libre de Bruxelles, Brussels, Belgium.
  • Peña L; Spanish Breast Cancer Cooperative Group SOLTI, Barcelona, Spain.
  • Loi S; Division of Research and Cancer Medicine, Peter MacCallum Cancer Centre, East Melbourne, Australia.
  • Rosa DD; Hospital Moinhos de Vento, Porto Alegre, Brazil.
  • Chia S; Department of Medical Oncology, BC Cancer Agency, Vancouver, Canada.
  • Wardley A; The Christie/NIHR Clinical Research Facility, Manchester, UK.
  • Ueno T; Department of Breast Surgery, Kyoto University Hospital, Kyoto, Japan.
  • Rossari J; Hospital Moinhos de Vento, Porto Alegre, Brazil.
  • Eidtmann H; Department of Obstetrics and Gynecology, Campus Kiel, University Hospital Kiel, Kiel, Germany.
  • Armour A; Novartis, Cambridge.
  • Piccart-Gebhart M; Institut Jules Bordet, Université Libre de Bruxelles, Brussels, Belgium.
  • Rimm DL; Department of Breast Medical Oncology, Yale University, Yale Cancer Center, New Haven, USA.
  • Baselga J; Memorial Sloan-Kettering Cancer Center, Memorial Hospital, New York, USA.
  • Pusztai L; Department of Breast Medical Oncology, Yale University, Yale Cancer Center, New Haven, USA.
Ann Oncol ; 28(1): 128-135, 2017 01 01.
Article en En | MEDLINE | ID: mdl-28177460
Asunto(s)
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Quinazolinas / Neoplasias de la Mama / Protocolos de Quimioterapia Combinada Antineoplásica / Receptor ErbB-2 / Trastuzumab Tipo de estudio: Clinical_trials / Prognostic_studies / Risk_factors_studies Límite: Female / Humans Idioma: En Revista: Ann Oncol Asunto de la revista: NEOPLASIAS Año: 2017 Tipo del documento: Article País de afiliación: Estados Unidos Pais de publicación: Reino Unido
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Quinazolinas / Neoplasias de la Mama / Protocolos de Quimioterapia Combinada Antineoplásica / Receptor ErbB-2 / Trastuzumab Tipo de estudio: Clinical_trials / Prognostic_studies / Risk_factors_studies Límite: Female / Humans Idioma: En Revista: Ann Oncol Asunto de la revista: NEOPLASIAS Año: 2017 Tipo del documento: Article País de afiliación: Estados Unidos Pais de publicación: Reino Unido